Kaitlyn D’Onofrio

DocwireNews

In a recent&nbsp;phase 3, randomized controlled, double-blind international study, researchers assessed the effectiveness of methotrexate (MTX) and etanercept (ETN) by themselves and in combination in psoriatic arthritis (PsA) patients.&nbsp;The findings, presented at the&nbsp;2018 ACR/ARHP Annual Meeting, concluded that etanercept&nbsp;monotherapy and in combination with methotrexate were both more effective treatment options compared with MTX on its own, and the addition of MTX to ETN did not improve efficacy compared with standalone ETN.&nbsp;<a href="https://twitter.com/ncbibooks/status/1056918335697420289">https://twitter.com/ncbibooks/status/1056918335697420289</a>Patients considered to have active&nbsp;PsA&nbsp;(n = 851; mean age, 48.4 years; median&nbsp;PsA&nbsp;duration, 0.6 years) based on the Classification Criteria for Psoriatic Arthritis were&nbsp;classified&nbsp;into&nbsp;three groups:&nbsp;ETN 50 mg plus MTX 20 mg weekly (combo,&nbsp;n&nbsp;= 283),&nbsp;ETN 50 mg plus oral placebo weekly (ETN-mono,&nbsp;n&nbsp;= 284),&nbsp;and&nbsp;MTX 20 mg plus injectable placebo weekly (MTX-mono,&nbsp;n&nbsp;= 284).&nbsp;The study&rsquo;s primary endpoint was&nbsp;American College of Rheumatology (ACR)20 response at week 24. Other endpoints included Minimal Disease Activity (MDA) response after 24 weeks,&nbsp;other measures of inflammatory arthritis, radiographic progression, severity of non-articular disease manifestations, and patient-reported outcomes.&nbsp;<a href="https://twitter.com/RheumatologyMed/status/1057650475137404928">https://twitter.com/RheumatologyMed/status/1057650475137404928</a>At week 24,&nbsp;ETN-mono patients had significantly greater ACR20 and MDA response rates when compared with MTX-mono patients&nbsp;(ACR20: 60.9% vs 50.7% [P&nbsp;=&nbsp;0.029]; MDA: 35.9% vs 22.9% [P&nbsp;=&nbsp;0.005]), as did the combo&nbsp;group compared with the&nbsp;MTX-mono&nbsp;cohort&nbsp;(ACR20: 65.0% vs 50.7%&nbsp;[P&nbsp;=&nbsp;0.005]; MDA: 35.7% vs 22.9% [P&nbsp;= 0.005]).&nbsp;By week 48, the combo and ETN-mono groups showed less radiographic progression than the MTX-mono patients. Outcomes for combo and ETN-mono patients were similar, the researchers noted, with some skin outcome variations.&nbsp;&ldquo;This is the first head-to-head comparison of MTX and a&nbsp;TNFi&nbsp;to address fundamental questions in the treatment of&nbsp;PsA,&rdquo; the researchers wrote, adding, &ldquo;These results support the use of ETN as monotherapy for&nbsp;PsA.&rdquo;&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/on-drug-and-drug-free-remission-by-baseline-symptom-duration-abatacept-with-methotrexate-in-patients-with-early-rheumatoid-arthritis/">On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/tocilizumab-monotherapy-compare/">How Does Tocilizumab Monotherapy Compare to Tocilizumab Plus Methotrexate?</a>&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/herpes-zoster-tofacitinib-risk/">Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate</a>&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/rheumatoid-arthritis-results-nationwide/">Risk factors associated with inadequate control of disease activity in elderly patients with rheumatoid arthritis: Results from a nationwide Korean College of Rheumatology Biologics (KOBIO) registry</a>&nbsp;Source:&nbsp;<a href="https://acrabstracts.org/abstract/etanercept-and-methotrexate-as-monotherapy-or-in-combination-in-patients-with-psoriatic-arthritis-a-phase-3-double-blind-randomized-controlled-study/">American College of Rheumatology&nbsp;</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Study Evaluates Etanercept and Methotrexate Alone and in Combination to Treat Psoriatic Arthritis

Rheumatology

In a recent phase 3, randomized controlled, double-blind international study, researchers assessed the effectiveness of methotrexate (MTX) and etanercept (ETN) by themselves ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe